重视角膜胶原交联术在眼科的临床应用和研究

摘要

Corneal collagen cross-linking (CXL) technique has evolved for more than 10 years and used for ectasia disease as a routine treatment in Europe.It has been proved to be a very effective technique to halt the progression of cornea ectasia diseases as well as a very promising technique for other clinical applications in ophthalmology.Currently the treatment is under the approval by SFDA.Being a nation,extremely lacking of donor corneas,high volume of corneal refractive surgery,sever infective keratitis still being one of the main cause to blindness,we should attach importance to understand CXL technique as well as advocate and promote its clinical application and research.%角膜胶原交联术经过十余年发展,在欧洲已成为治疗膨隆性角膜病变的常规手段,可以有效地阻止角膜膨隆的进展,同时在眼科临床其他方面也有很好的应用前景.目前该技术仍在国家审批过程中,我国作为角膜植片严重匮乏、广泛大量开展角膜屈光手术、严重感染性角膜炎仍是主要致盲因素之一的国家,我们亟需重视对角膜胶原交联术的认识,倡导并推动该技术在我国眼科的研究和临床应用.